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Drug Targeting in Metastatic Melanoma
A Hauschild
Department of Dermatology, University of Kiel, Germany
The efficacy of current treatment modalities for stage IV melanoma patients is
weak. Therefore, new treatment modalities are urgently needed. The molecular
identification of therapeutic targets, which are involved in tumor progression led to
the development of new agents. Among the possible targets are molecules of the
signal transduction pathway since as Ras, Raf and MEK, the proteasome, histone
deacetylases, methyltransferases, and melanoma-induced angiogenesis. Currently,
there are numerous phase I-III trials with interesting agents and translational
research programs. The most promising results were seen with Sorafenib, a multi-
kinase inhibitor, in combination with Carboplatin and Paclitaxel. The US trial in 54
mainly pretreated advanced melanomas demonstrated 37% partial responses and
48% stabilized diseases. Currently, an international and a US/Canadian trial are
evaluating this approach in metastatic melanoma patients. Regarding other
molecules, it is unclear yet, whether they have a potential as a monotherapy or
more likely as combinations with other molecules that interfere with the same
pathways or alternative anti-tumor mechanisms. Among these are histone
deacetylase inhibitors like MS-275 and integrin receptor inhibitors like Vitaxin
(Medi-522) or CNTO-95. Another interesting approach is the augmentation of T-
cell responses by the use of CTLA-4 antibodies, which inhibit regulatory T-
lymphocytes. Early trials demonstrated efficacy particularly in patients, who
developed autoimmune phenomenons during treatment. Phase III trials using
CTLA-4 antibodies alone, combined with vaccination or Dacarbazine are under-
way.In conclusion, several different treatment approaches are currently under
evaluation, which have in principal the capacity to define better standards of care.
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Interleukin-2 Based Adjuvant Immuno-Therapy for Melanoma Patients
L Bianchi
Department of Dermatology, Tor Vergata University of Rome, Rome, Italy
Reports of spontaneous disease regression in melanoma and its immunogenic
behaviour have currently supported immuno-therapeutic approaches based on
cytokines, vaccines, monoclonal antibodies, gene therapy. Interleukin-2 (IL-2) is a
lymphokine with a central role in immune regulation. It activates cytotoxic
lymphocytes, stimulates secondary cytokines, activates natural killer cells and
macrophages, activates B-cells, induces release of hormones and activates
complement factors. IL-2 was described to be efficient in stage IV melanoma as
single agent, combined with chemotherapy or with immunologically active cells.
Initial studies showed a response rate of 15-20% and a complete response rate of
B6% with a very small chance of long-term remission. Randomised clinical trials
failed to demonstrate a convincing evidence that adding IFN-a to IL-2 was
beneficial. Phase II–III studies of IL-2 based immunochemotherapy indicated
durable complete response in a small fraction of patients. Nevertheless, a defined
treatment schedule for IL-2-based therapy in metastatic melanoma remains
debated. Furthermore, the increasingly accurate melanoma staging led to better
identify patients with sufficiently high-risk of relapse. In this purpose, intermittent
low-dose subcutaneous IL-2 in adjuvant post-surgery and/or after chemotherapy
has been investigate to reduce the risk of disease relapse and prolong disease-free
survival. The follow-up and adverse events in 7 high-risk patients (stage IB, IIA, IIC,
IIII), 2/7 treated with intravenous dacarbazine (750 mg/mq on day 1, monthly) and
subcutaneous IL-2 (6 million units on day 2–5, 16–19, monthly), 5/7 with
subcutaneous IL-2, as single agent (3 million units on day 1–5, 8–12, monthly),
are reported and discussed.
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Critical Questions in Melanoma Biological Immunotherapy Develop-
ment?
B Dreno
Department of Skin Oncology, Nantes, France
Biological immunotherapy is represented by Tumor infiltrating Lymphocytes (TIL:
i.e. injection of T lymphocytes generated and selected ex-vivo from blood or from
the tumor) which is adoptive immunotherapy. At the clinical level, previously it has
been shown that TIL were able to induce a regression of metastatic lesion (mean
30%) but without increase the overall survival (quick relapse). Recently five crucial
points have been identified for the efficacy of this biological immunotherapy
1- The tumour burden
A strong interaction exists between TIL used as adjuvant therapy in melanoma stage
III (AJCC) and the number of invaded lymph nodes. Indeed, the injection of TIL in
patients with only one invaded lymph node was associated with an increased
relapse free survival and an overall survival;
2- Migration of TIL to the metastatic stage
Four papers, now with an immunological follow-up have shown the correlation
between the therapeutic benefit and the survival and the preferential migration of
specific T lymphocytes to the tumor sites.
3- The specific TIL against melanoma antigens
The therapeutic benefit is directly related to the percentage of tumor antigen
specific T lymphocytes, against melanoma obtained in the expansion.
4- The melanoma antigens
Recent results strongly suggest that the infusion of reactive Melan-A/MART-1
specific lymphocytes was associated with clinical efficiency of TIL treatment.
Furthermore, the amount of such lymphocytes seemed to be critical for patients
bearing more than one invaded lymph nodes before the treatment.
5- The mechanisms of escape to adoptive immunotherapy
Three mechanisms could decrease the efficacy of adoptive immunotherapy:
T reg cells (CD4þ CD25þ Fox p3) presents in the final expansion injected to the
patient
Suppressive cytokines secreted in situ by tumor cells (IL-10, TGFby.)
Decrease expression of melanoma expression by tumor cells
Studies are on going to try to answer to this last crucial question.
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Future Directions of Multimodality Treatment in Melanoma
C Garbe
Division of Dermatooncology, Department of Dermatology, Eberhard Karls
University, Tu¨bingen, Germany
Malignant melanoma is known as one of the tumors with most effective treatment
resistance mechanisms among all cancers. Drug resistance to chemotherapeutics
results in low response rates of about 10 % in monochemotherapy and up to 20 %
in polychemotherapy. It is still unknown whether drug targeting in melanoma will
substantially increase treatment responses. Therefore, there is an urgent need for
integration of additional treatment modalities into the therapeutic strategy in
metastasized melanoma. First, the indication for surgical metastasectomy has to be
checked in all melanoma patients with distant metastases. New imaging techniques
provide a more complete picture of the pattern of metastases and enable surgical
resection also in multiple organs. Resection of visceral metastases has to be
considered particularly in metastases of brain, lung, liver and bone. Radiotherapy is
an effective option in metastases of the brain, bones and soft tissue. Its effect can be
enhanced particularly in soft tissue by hyperthermia. Finally, the role of vaccination
treatments has to be defined in relationship to chemotherapy and targeted
therapies. Vaccination therapies may become particularly an option in patients
after surgical metastasectomy. Intelligent strategic combinations of treatment
modalities are warranted in order to prolong patient survival in the stage of distant
metastases.
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